695 studies found for:    "melphalan"
Show Display Options
Rank Status Study
1 Recruiting A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Busulfan;   Drug: Melphalan;   Other: Questionnaire;   Drug: G-CSF;   Drug: High Dose Melphalan;   Procedure: Stem cell transplant
2 Recruiting Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
Condition: Metastatic Melanoma
Intervention: Drug: Melphalan
3 Terminated Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage
Condition: Retinoblastoma
Intervention: Drug: Melphalan
4 Completed
Has Results
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Siltuximab11 mg/kg;   Drug: Siltuximab 8.3 mg/kg or 11 mg/kg;   Drug: Velcade (bortezomib);   Drug: Melphalan;   Drug: Prednisone
5 Active, not recruiting
Has Results
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
Condition: Multiple Myeloma
Interventions: Drug: melphalan;   Drug: topotecan (TPT);   Procedure: Autologous Stem Cell Rescue
6 Active, not recruiting
Has Results
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Conditions: Primary Systemic Amyloidosis;   Light Chain Deposition Disease
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan;   Genetic: microarray analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
7 Completed
Has Results
Lenalidomide and High-Dose Melphalan
Conditions: Myeloma;   Stem Cell Transplantation
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Procedure: Stem Cell Infusion
8 Terminated Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Melphalan;   Drug: Dexamethasone;   Behavioral: Questionnaires
9 Recruiting Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib-Melphalan;   Drug: Melphalan
10 Completed
Has Results
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Drug: amifostine trihydrate;   Procedure: peripheral blood stem cell transplantation;   Genetic: fluorescence in situ hybridization;   Procedure: bone marrow ablation with stem cell support
11 Terminated Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma
Condition: Newly Diagnosed, Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: melphalan, prednisone;   Drug: melphalan, prednisone, thalidomide
12 Recruiting Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Busulfan;   Drug: Palifermin;   Drug: Panobinostat;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Dexamethasone acetate;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Procedure: Stem Cell Transplant
13 Completed
Has Results
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: melphalan;   Drug: dexamethasone;   Drug: bortezomib
14 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
15 Completed Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan
16 Completed TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Topotecan;   Drug: Cyclophosphamide;   Drug: Melphalan;   Other: Peripheral Blood Stem Cells
17 Recruiting A Pharmacokinetic Study of Melphalan in Children
Condition: Hematopoietic Stem Cell Transplantation
Intervention: Drug: Melphalan
18 Recruiting Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Conditions: Hepatocellular Carcinoma;   Intrahepatic Cholangiocarcinoma
Interventions: Device: Delcath Hepatic Delivery System;   Drug: Melphalan
19 Active, not recruiting High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Condition: Lymphoma
Interventions: Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplantation;   Drug: Palifermin
20 Active, not recruiting Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
Conditions: Multiple Myeloma;   Newly Diagnosed Patients
Interventions: Drug: Melphalan;   Drug: Lenalidomide;   Drug: Prednisone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years